WLWT: Benefits of Vitamin D and COVID-19
February 22, 2021
Richard Becker, MD, director of the University of Cincinnati Heart, Lung and Vascular Institute, speaks with WLWT-TV News about role vitamins might play in battling COVID-19.
35 Results
Fox 19: Taking care of your heart
February 1, 2021
University of Cincinnati cardiologist Richard Becker, MD, says heart disease remains the leading killer of American women and men even though the COVID-19 pandemic was responsible for a spike in deaths during periods of 2020. Dr. Becker reminds residents during American Heart Month to practice good heart health.
COVID-19 continues to rage, but so does cardiovascular disease
January 27, 2021
UC cardiologists are hoping to call attention to the dangers still posed by heart disease during February, which is American Heart Month. The first Friday of the month is designated National Wear Red Day by Go Red for Women and the American Heart Association to call attention to the risk heart disease presents for women. Heart disease has traditionally been the top killer of American women and men.
Cincinnati Edition: COVID 'long haulers' face symptoms months...
January 4, 2021
Richard Becker, MD, director of the UC Heart, Lung and Vascular Institute, spoke with WVXU for a segment about his interaction with former COVID patients who are still battling health ailments related to fighting off the pandemic. Becker said worldwide there are 80 million known cases of COVID-19 and 1.7 million who died as a result. That means more than 78 million people have survived infection including 600,000 in the state of Ohio.
Cincinnati Edition: Cardiologist develops COVID app to reach...
December 1, 2020
Donald Lynch, MD, assistant professor of cardiovascular health and disease in the University of Cincinnati College of Medicine, is partnering with researchers in Missouri and Georgia to create a smartphone app that delivers COVID-19 information tailored to Black communities.
TCTMD: Bleeds on anticoagulants for atrial fibrillation can...
November 17, 2020
Richard Becker, MD, director of the University of Cincinnati Heart, Lung and Vascular Institute, also weighed in on a research finding out of Spain. The observational study of 9,000 elderly patients on oral anticoagulants suggests bleeding thought related to antithrombotic therapy may be an early warning sign for as-yet-undetected cancer.
WCPO: Local doctor helps design app to help Black community...
November 15, 2020
Donald Lynch, MD, assistant professor in the UC Division of Cardiovascular Health and Disease, is developing a smartphone app designed to provide better information and education that will reach African-American communities which are disproportionately affected by the COVID-19 pandemic.
UC researchers tackle cardiomyopathy in the lab
November 14, 2020
Two investigators in the University of Cincinnati College of Medicine present their research findings at the 2020 American Heart Association Virtual Scientific Sessions. Brittany Duncan, a doctoral student in molecular, cellular and biochemical pharmacology, is testing an investigational drug’s impact on diabetic cardiomyopathy in animal models. Her colleague, Sholeh Bazrafshan, MD, a visiting scholar, is examining the impact exercise-related stress can have on individuals who carry a genetic variant of a heart protein linked to hypertrophic cardiomyopathy, commonly known as an enlarged heart.
Decoding heart-brain talk
November 3, 2020
Deeptankar DeMazumder, MD, PhD, assistant professor in the University of Cincinnati College of Medicine, is the recipient of a 2020 National Institutes of Health Director's New Innovator Award. The honor supports unusually innovative research from early career investigators who are within 10 years of their final degree or clinical residency and have not yet received an equivalent NIH grant.
UC scientist studies role of protein in skeletal muscle disorders
November 2, 2020
A University of Cincinnati researcher has received a five-year $2.2 million grant to study the role a protein in muscles plays in the development of a rare disease known as distal arthrogryposis. The grant is from the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Healthline: Diet soda no better than regular soda for heart...
October 29, 2020
Richard Becker, MD, director of the UC Heart, Lung and Vascular Institute, and UC Health cardiologist, spoke with Healthline about a new study that finds people who want to stay heart healthy should avoid drinking artificially sweetened beverages like diet soda. Becker says water should be the beverage of choice.
Researcher develops app to reach Black community with COVID-19...
October 29, 2020
Donald Lynch, MD, a University of Cincinnati cardiologist, is partnering with researchers in St. Louis and rural Georgia to develop a smartphone app that will deliver COVID-19 information and education that is targeted toward Black communities.
Contagion Live: Targeting Lung Blood Vessel Inflammation in...
September 30, 2020
Richard Becker, MD, director of the UC Heart, Lung and Vascular Institute, was interviewed by a reporter for Contagion Live about a new phase 2 clinical trial UC and UC Health are conducting using the drug razuprotafib, to lessen inflammation of the blood vessels in COVID-19 patients. Razuprotafib activates a key pathway for stabilizing blood vessels in the lungs and may prevent or treat respiratory distress in COVID-19 patients.
Cincinnati Public Radio: Researchers Zeroing In On Blood Vessels...
September 28, 2020
Richard Becker, MD, and Duncan Hite, MD, both professors in the UC College of Medicine and UC Health physicians, spoke with WVXU reporter Ann Thompson about a phase 2 clinical trial underway at UC/UC Health to determine the safety and efficacy of the drug razuprotafib in treating COVID-19 patients. UC is one of 20 sites across the nation participating in the trial.
UC researchers to study drug’s effects on COVID-19 patients
September 22, 2020
Researchers at the University of Cincinnati and UC Health will host a Phase 2 clinical trial (NCT04511650) to examine the effects of a drug that targets blood vessel inflammation and injury in patients with COVID-19. They will study the effects of razuprotafib, an investigational drug that activates a key pathway for stabilizing blood vessels in the lung and other organs in patients with moderate to severe cases of the respiratory illness caused by the novel coronavirus SARS-CoV-2. The drug may prevent and treat respiratory distress in COVID-19 patients. The Phase 2 clinical trial will assess safety, tolerability and efficacy of razuprotafib.